These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 28382278)

  • 1. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9.
    Li H; Sheng C; Wang S; Yang L; Liang Y; Huang Y; Liu H; Li P; Yang C; Yang X; Jia L; Xie J; Wang L; Hao R; Du X; Xu D; Zhou J; Li M; Sun Y; Tong Y; Li Q; Qiu S; Song H
    Front Cell Infect Microbiol; 2017; 7():91. PubMed ID: 28382278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
    Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
    Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of CRISPR/Cas9 Technology to HBV.
    Lin G; Zhang K; Li J
    Int J Mol Sci; 2015 Nov; 16(11):26077-86. PubMed ID: 26540039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.
    Martinez MG; Combe E; Inchauspe A; Mangeot PE; Delberghe E; Chapus F; Neveu G; Alam A; Carter K; Testoni B; Zoulim F
    mBio; 2022 Apr; 13(2):e0288821. PubMed ID: 35389262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
    Zhang J; Zhang Y; Khanal S; Cao D; Zhao J; Dang X; Nguyen LNT; Schank M; Wu XY; Jiang Y; Ning S; Wang L; El Gazzar M; Moorman JP; Guo H; Yao ZQ
    J Med Virol; 2023 Jul; 95(7):e28952. PubMed ID: 37455550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
    Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
    World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus.
    Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V
    Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 System with Dual gRNAs Synergically Inhibit Hepatitis B Virus Replication.
    Fei L; Sun S; Yang Q; Huang Y; Li Q; Tao S; Chen L
    Discov Med; 2024 Jun; 36(185):1169-1179. PubMed ID: 38926103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.
    Yang HC; Chen PJ
    Virus Res; 2018 Jan; 244():304-310. PubMed ID: 28627393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA.
    Seeger C; Sohn JA
    Mol Ther; 2016 Aug; 24(7):1258-66. PubMed ID: 27203444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models.
    Yi J; Lei X; Guo F; Chen Q; Chen X; Zhao K; Zhu C; Cheng X; Lin J; Yin H; Xia Y
    Antiviral Res; 2023 Jul; 215():105618. PubMed ID: 37142191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Effective Molecular Target Site in Hepatitis B Virus S Gene for Cas9 Cleavage and Mutational Inactivation.
    Li H; Sheng C; Liu H; Liu G; Du X; Du J; Zhan L; Li P; Yang C; Qi L; Wang J; Yang X; Jia L; Xie J; Wang L; Hao R; Xu D; Tong Y; Zhou Y; Zhou J; Sun Y; Li Q; Qiu S; Song H
    Int J Biol Sci; 2016; 12(9):1104-13. PubMed ID: 27570484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome.
    Liu X; Hao R; Chen S; Guo D; Chen Y
    J Gen Virol; 2015 Aug; 96(8):2252-2261. PubMed ID: 25904148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse.
    Zhu W; Xie K; Xu Y; Wang L; Chen K; Zhang L; Fang J
    Virus Res; 2016 Jun; 217():125-32. PubMed ID: 27049051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus.
    Sakuma T; Masaki K; Abe-Chayama H; Mochida K; Yamamoto T; Chayama K
    Genes Cells; 2016 Nov; 21(11):1253-1262. PubMed ID: 27659023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
    Peng C; Lu M; Yang D
    Virol Sin; 2015 Oct; 30(5):317-25. PubMed ID: 26511989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.
    Kennedy EM; Bassit LC; Mueller H; Kornepati AVR; Bogerd HP; Nie T; Chatterjee P; Javanbakht H; Schinazi RF; Cullen BR
    Virology; 2015 Feb; 476():196-205. PubMed ID: 25553515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas.
    Yang YC; Yang HC
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered extracellular vesicles for delivering functional Cas9/gRNA to eliminate hepatitis B virus cccDNA and integration.
    Zeng W; Zheng L; Li Y; Yang J; Mao T; Zhang J; Liu Y; Ning J; Zhang T; Huang H; Chen X; Lu F
    Emerg Microbes Infect; 2024 Dec; 13(1):2284286. PubMed ID: 37982370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gRNA-miRNA-gRNA Ternary Cassette Combining CRISPR/Cas9 with RNAi Approach Strongly Inhibits Hepatitis B Virus Replication.
    Wang J; Chen R; Zhang R; Ding S; Zhang T; Yuan Q; Guan G; Chen X; Zhang T; Zhuang H; Nunes F; Block T; Liu S; Duan Z; Xia N; Xu Z; Lu F
    Theranostics; 2017; 7(12):3090-3105. PubMed ID: 28839466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.